{"analyses":[{"ciLowerLimit":"1.06","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.26","groupDescription":"SCLC Arm N Expansion as compare to SCLC Arm N-I Dose Level 2- Expansion","groupIds":["OG013","OG014"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0309","paramType":"Odds Ratio (OR)","paramValue":"2.12","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"27.3","value":"5.6"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"18.5","value":"0.0"},{"groupId":"OG003","lowerLimit":"4.9","upperLimit":"22.9","value":"11.9"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG005","lowerLimit":"13.3","upperLimit":"38.9","value":"24.5"},{"groupId":"OG006","lowerLimit":"2.1","upperLimit":"18.5","value":"7.7"},{"groupId":"OG007","lowerLimit":"0","upperLimit":"18.5","value":"0.0"},{"groupId":"OG008","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG009","lowerLimit":"0.0","upperLimit":"18.5","value":"0.0"},{"groupId":"OG010","lowerLimit":"0.8","upperLimit":"22.1","value":"6.7"},{"groupId":"OG011","lowerLimit":"7.3","upperLimit":"21.6","value":"13.3"},{"groupId":"OG012","lowerLimit":"15.8","upperLimit":"39.1","value":"26.2"},{"groupId":"OG013","lowerLimit":"6.9","upperLimit":"17.9","value":"11.6"},{"groupId":"OG014","lowerLimit":"14.1","upperLimit":"31.5","value":"21.9"},{"groupId":"OG015","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"},{"groupId":"OG016","lowerLimit":"9.1","upperLimit":"30.9","value":"18.2"},{"groupId":"OG017","lowerLimit":"8.1","upperLimit":"16.6","value":"11.8"},{"groupId":"OG018","lowerLimit":"16.0","upperLimit":"29.6","value":"22.3"},{"groupId":"OG019","lowerLimit":"16.4","upperLimit":"36.8","value":"25.6"},{"groupId":"OG020","lowerLimit":"28.1","upperLimit":"48.8","value":"38.0"},{"groupId":"OG021","lowerLimit":"18.7","upperLimit":"36.5","value":"26.9"},{"groupId":"OG022","lowerLimit":"4.1","upperLimit":"26.2","value":"12.2"},{"groupId":"OG023","lowerLimit":"1.5","upperLimit":"19.1","value":"7.0"},{"groupId":"OG024","lowerLimit":"2.7","upperLimit":"22.6","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"59"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"49"},{"groupId":"OG006","value":"52"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"18"},{"groupId":"OG010","value":"30"},{"groupId":"OG011","value":"98"},{"groupId":"OG012","value":"61"},{"groupId":"OG013","value":"147"},{"groupId":"OG014","value":"96"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"55"},{"groupId":"OG017","value":"245"},{"groupId":"OG018","value":"157"},{"groupId":"OG019","value":"78"},{"groupId":"OG020","value":"92"},{"groupId":"OG021","value":"104"},{"groupId":"OG022","value":"41"},{"groupId":"OG023","value":"43"},{"groupId":"OG024","value":"42"}],"units":"Participants"}],"description":"The number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of treated participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W","id":"OG000","title":"TNBC Arm N"},{"description":"Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W","id":"OG001","title":"TNBC Arm N-I Dose Level 1"},{"description":"Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W","id":"OG002","title":"TNBC Arm N-I Dose Level 2"},{"description":"Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W","id":"OG003","title":"GC Arm N"},{"description":"Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W","id":"OG004","title":"GC Arm N-I Dose Level 1"},{"description":"Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W","id":"OG005","title":"GC Arm N-I Dose Level 2"},{"description":"Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W","id":"OG006","title":"GC Arm N-I Dose Level 2b"},{"description":"Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W","id":"OG007","title":"PC Arm N"},{"description":"Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W","id":"OG008","title":"PC Arm N-I Dose Level 1"},{"description":"Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W","id":"OG009","title":"PC Arm N-I Dose Level 2"},{"description":"Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off","id":"OG010","title":"PC Arm N-I Dose Level 2d"},{"description":"Small cell lung cancer (SCLC) participants treated in Pre-expansion Cohort with Nivolumab 3 mg/kg Q2W","id":"OG011","title":"SCLC Arm N - Pre-expansion"},{"description":"Small cell lung cancer (SCLC) treated participants in Pre-expansion cohort treated with Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W","id":"OG012","title":"SCLC Arm N-I Dose Level 2 - Pre-expansion"},{"description":"Small cell lung cancer (SCLC) expansion cohort participants:Nivolumab monotherapy (3 mg/kg) Q2W","id":"OG013","title":"SCLC Arm N Expansion"},{"description":"Small cell lung cancer (SCLC) expansion cohort participants Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2Wi","id":"OG014","title":"SCLC Arm N-I Dose Level 2- Expansion"},{"description":"Small cell lung cancer (SCLC) participants treated with Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3mg/kg) Q2W","id":"OG015","title":"SCLC Arm N-I Dose Level 1 -"},{"description":"Small cell lung cancer (SCLC) treated participants treated with Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W","id":"OG016","title":"SCLC Arm N-I Dose Level 2b"},{"description":"Small cell lung cancer (SCLC) for all treated participants with Nivolumab 3 mg/kg Q2W","id":"OG017","title":"SCLC Arm N- All Treated"},{"description":"Small cell lung cancer (SCLC) all treated participants with Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses","id":"OG018","title":"SCLC Arm N-I Dose Level 2 - All Treated"},{"description":"Bladder cancer (BC) participants: Nivolumab 3 mg/kg Q2W","id":"OG019","title":"BC Arm N"},{"description":"Bladder cancer (BC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W","id":"OG020","title":"BC Arm N-I Dose Level 2"},{"description":"Bladder cancer (BC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W","id":"OG021","title":"BC Arm N-I Dose Level 2b"},{"description":"Ovarian cancer (OC) participants:\n\nNivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W","id":"OG022","title":"OC Arm N-I Dose Level 2"},{"description":"Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses,then nivolumab (3 mg/kg) Q2W","id":"OG023","title":"OC Arm N-I Dose Level 2b:"},{"description":"Ovarian cancer (OC) participants: Nivolumab (3 mg/kg) Q2W + ipilimumab (1 mg/kg) Q6W","id":"OG024","title":"OC Arm N-I Dose Level 2c:"}],"paramType":"NUMBER","populationDescription":"All Treated Participants","reportingStatus":"POSTED","timeFrame":"60 months","title":"Objective Response Rate ( ORR )","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}